ML390

CAS No. 2029049-79-2

ML390( —— )

Catalog No. M22425 CAS No. 2029049-79-2

ML390 exerts its potent differentiation effect on multiple leukemia models.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
10MG 39 In Stock
25MG 69 In Stock
50MG 105 In Stock
100MG 188 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ML390
  • Note
    Research use only, not for human use.
  • Brief Description
    ML390 exerts its potent differentiation effect on multiple leukemia models.
  • Description
    ML390 exerts its potent differentiation effect on multiple leukemia models.
  • In Vitro
    ML390 is active with an ED50 of ~2 μM in murine and human AML cell lines. In vitro, treatment of Lys-GFP-ER-HoxA9 cells with ML390 for 48 hr inhibits DHODH activity, leading to the dramatic (>500-fold) accumulation of the upstream metabolite DHO and the depletion of uridine and other downstream metabolites.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2029049-79-2
  • Formula Weight
    406.4
  • Molecular Formula
    C21H21F3N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:27 mg/mL (66.44 mM)
  • SMILES
    FC(F)(F)Oc1ccc(cc1)C(=O)NCCC(=O)N[C@@H]1CCCc2ccccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sykes DB et al. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. National Center for Biotechnology Information (US); 2010-2013 Dec 15.
molnova catalog
related products
  • Anemarrhenasaponin I...

    Anemarrhenasaponin Ia, an useful anti-inflammation reagent, is isolated from Anemarrhenae rhizome. Anemarrhenasaponin Ia inhibits the generation of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide.

  • ICCB280

    ICCB280 was capable of inducing differentiation and apoptosis of ATRA-resistant patient blasts strongly signify that the activity of this compound can overcome resistance to other current therapies for AML with an unfavorable prognosis.

  • Daphnoretin

    Daphnoretin has anticancer effects on leukemia, osteosarcoma and uterine cervix cancer cells, might through promoting apoptosis in a mitochondria-mediated way.